Advertisement

Long-term treatment of hypertrophic cardiomyopathy with verapamil or propranolol in matched pairs of patients: Results of a multicenter study

  • G. Kober
  • R. Hopf
  • G. Biamino
  • P. Bubenheimer
  • K. Förster
  • K. H. Kuck
  • P. Hanrath
  • K.-E. v. Olshausen
  • M. Schlepper
  • M. Kaltenbach
Conference paper

Abstract

According to definition, hypertrophic cardiomyopathy (HCM) is a myocardial disease of unknown origin. Initially, types with and without obstruction of the left or right ventricle were separated as different diseases.

Keywords

Hypertrophic Cardiomyopathy Hypertrophic Obstructive Cardiomyopathy Propranolol Treatment Idiopathic Hypertrophic Subaortic Stenosis Left Ventricular Biopsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Harrison D, Braunwald E, Glich G, Mason DT, Chidsey CA, Ross J Jr (1964) Effects of 13adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 29: 84PubMedGoogle Scholar
  2. 2.
    Lösse B, Kuhn H, Loogen F (1982) Functional results in medically and surgically treated patients with hypertrophie obstructive cardiomyopathy. In: Kaltenbach M, Epstein SE (eds), Hypertrophic Cardiomyopathy. Springer Berlin—Heidelberg—New York, pp, 251–260Google Scholar
  3. 3.
    Kuhn H, Loogen F (1978) Die Anwendung von Beta-Rezeptorenblockern bei hypertrophischer Kardiomyopathy ( HOCM ). Internist 19: 527–531Google Scholar
  4. 4.
    Kober G, Schmidt-Moritz A, Hopf R, Kaltenbach M (1983) Long-term treatment of hypertrophic obstructive cardiomyopathy — usefulness of verapamil. Eur Heart J 4: 165–174PubMedGoogle Scholar
  5. 5.
    Hopf R, Rodrian S, Kaltenbach M (1986) Behandlung der hypertrophen Kardiomyopathy mit Kalziumantagonisten. Therapiewoche 36: 1433–1454Google Scholar
  6. 6.
    Lösse B, Kuhn H, Loogen F (1982) Klinische und hämodynamische Effekte von Verapamil bei hypertrophischer obstruktiver Kardiomyopathie. Z Kardiol 71: 813–819PubMedGoogle Scholar
  7. 7.
    Maron BJ, Merill, WH, Freier PA, Kent KM, Epstein SE, Morrow AG (1978) Long-term clinical course and symptomatic status of patients after operation for hypertrophie subaortic stenosis. Circulation 57: 1205–1213PubMedGoogle Scholar
  8. 8.
    Agnew TM, Barratt-Boyes BG, Brandt PWT, Roche AHG, Lowe JB, O’Brien KP (1977) Surgical resection in idiopathic hypertrophie subaortic stenosis with a combined approach through aorta and left ventricle: a long-term follow-up study in 49 patients. J Thor Cardiovasc Surg 74: 307–316Google Scholar
  9. 9.
    Bonow RO, Rosing DR, Bacharach SL, Green MV, Kent KM, Lipson LC, Maron BJ, Leon MB, Epstein SE (1981) Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 64: 787–796PubMedCrossRefGoogle Scholar
  10. 10.
    Landmark K, Sire S, Thaulow E, Amlie JP, Nitter-Hauge S (1982) Hemodynamic effects of nifedipine and propranolol in patients with hypertrophie obstructive cardiomyopathy. Br Heart J 48: 19–26PubMedCrossRefGoogle Scholar
  11. 11.
    Stenson RE, Flamm MD Jr, Harrison DC, Hancock EW (1973) Hypertrophie subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. Am J Cardiol 31: 763–773Google Scholar
  12. 12.
    Schmid P, Pavek P, Klein W (1979) Echokardiographische und hämodynamische Untersuchungen zur Beeinflussung der hypertrophischen obstruktiven Kardiomyopathie durch Verapamil. Z Kardiol 68: 89–92PubMedGoogle Scholar
  13. 13.
    Vincenzi M, Morlino T, Allegri P, Barbierei E, Cappelletti F, de Lio U, Ometto R, Maiolino P (1981) Changes in cardiovascular function induced by verapamil in healthy subjects and in patients with ischemic heart disease. Clin Cardiol 4: 15–21PubMedCrossRefGoogle Scholar
  14. 14.
    Spicer RL, Rocchini AP, Crowley DC, Vasiliades J, Rosenthal A (1983) Hemodynamic effects of verapamil in children and adolescents with hypertrophie cardiomyopathy. Circulation 67: 413–420PubMedCrossRefGoogle Scholar
  15. 15.
    Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE (1979) Verapamil therapy: a new approach to the pharmacologie treatment of hypertrophie cardiomyopathy. I. Hemodynamic effects. Circulation 60: 1201–1207Google Scholar
  16. 16.
    Rosing DR, Kent KM, Maron BJ, Epstein SE (1979) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophie cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 60: 1208–1213Google Scholar
  17. 17.
    Senn M, Hess OM, Krayenbühl HP (1982) Nifedipin in der Behandlung der hypertrophen, nichtobstruktiven Kardiomyopathie. Schweiz Med Wschr 112: 1312–1317PubMedGoogle Scholar
  18. 18.
    Hanrath P, Mathey DG, Kremer P, Sonntag F, Bleifeld W (1980) Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol 45: 1258–1264PubMedCrossRefGoogle Scholar
  19. 19.
    Frank MJ, Abdulla AM, Canedo MI, Saylors RE (1978) Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol 42: 993–1001PubMedCrossRefGoogle Scholar
  20. 20.
    Canedo MI, Frank MJ (1981) Therapy of hypertrophic cardiomyopathy: medical or surgical? Clinical and pathophysiologic considerations. Am J Cardiol 48: 383–388PubMedCrossRefGoogle Scholar
  21. 21.
    Wigle ED, Adelman AG, Felderhof CH (1974) Medical and surgical treatment of the cardiomyopathies. Circ Res 34, 35 Suppl II: 198–223Google Scholar
  22. 22.
    Goodwin JF (1974) Prospects and predictions for the cardiomyopathies. Circulation 50: 210–219PubMedGoogle Scholar
  23. 23.
    Loogen F, Krelhaus W, Kuhn H (1976) Verlaufsbeobachtungen der hypertrophischen obstruktiven Kardiomyopathie ( HOCM ). Z Kardiol 65: 511–521Google Scholar
  24. 24.
    Kaltenbach M, Hopf R (1982) Konservative medikamentöse Behandlung der hypertrophen Myokardiopathie. Z Kardiol 71: 795–805PubMedGoogle Scholar
  25. 25.
    Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y (1979) Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 42: 35–42PubMedCrossRefGoogle Scholar
  26. 26.
    Kaltenbach M, Hopf R, Keller M (1976) Calciumantagonistische Therapie bei hypertroph obstructiver Kardiomyopathie. Dtsch Med Wschr 101: 1284–1287PubMedCrossRefGoogle Scholar
  27. 27.
    Masini V, Ceci V, Malinconico U, Milazotto F (1981) Therapeutic evaluation of pindolol and verapamil in hypertrophic obstructive cardiomyopathy. G Ital Cardiol II: 1729–1737Google Scholar
  28. 28.
    Haberer T, Hess OM, Jenni R, Krayenbühl HP (1983) Hypertrophe obstruktive Kardiomyopathie: Spontanverlauf im Vergleich zu Langzeittherapie mit Propranolol und Verapamil. Z Kardiol 72: 487–493Google Scholar
  29. 29.
    Shand DG (1975) Drug therapy: propranolol. N Engl J Med 293: 280–285PubMedCrossRefGoogle Scholar
  30. 30.
    Chidsey C, Pine M, Favrot L, Smith S, Leonetti G, Morselli P, Zanchetti A (1976) The use of drug concentration measurements in studies of the therapeutic responses to propranolol. Postgr Med J 52 (S4): 26–32Google Scholar
  31. 31.
    Vucovich RA, Foley JE, Brown B, Willard DA, Buckley MO, Kelly D, Fitzgerald D, Torney W, Darragh A (1979) Effect of ß-blockers on exercise double product (systolic blood pressure X heart rate). Br J Clin Pharmacol 7 (Suppl 2): 167–172Google Scholar
  32. 32.
    Brody DA (1956) Theoretical analysis of intracavitory blood mass influence on the heart-lead relationship. Circ Res 4: 731PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1988

Authors and Affiliations

  • G. Kober
    • 1
    • 7
  • R. Hopf
    • 1
  • G. Biamino
    • 2
  • P. Bubenheimer
    • 3
  • K. Förster
    • 4
  • K. H. Kuck
    • 5
  • P. Hanrath
    • 5
  • K.-E. v. Olshausen
    • 6
  • M. Schlepper
    • 4
  • M. Kaltenbach
    • 1
  1. 1.Zentrum der Inneren Medizin, Abteilung für KardiologieUniversitätsklinikum FrankfurtGermany
  2. 2.Universitätsklinikum SteglitzBerlinGermany
  3. 3.Benedikt Kreutz-Rehabilitationszentrum Bad KrozingenGermany
  4. 4.Kerckhoff-Klinik Bad NauheimGermany
  5. 5.Kardiologische AbteilungII. Medizinische UniversitätsklinikHamburgGermany
  6. 6.Medizinische Klinik, Abteilung Innere Medizin IIIUniversität HeidelbergGermany
  7. 7.Abteilung für Kardiologie, Zentrum der Inneren MedizinKlinikum der UniversitätFrankfurt am MainGermany

Personalised recommendations